Novo Nordisk As Stock Analysis

Novo Stock Analysis Notes

The company has Price/Earnings To Growth (PEG) ratio of 1.17. Novo Nordisk AS last dividend was issued on the 31st of March 2025. The entity had 2:1 split on the 20th of September 2023. Novo Nordisk AS, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark. Novo Nordisk is traded on New York Stock Exchange in the United States. To find out more about Novo Nordisk AS contact Lars Jorgensen at 45 44 44 88 88 or learn more at https://www.novonordisk.com.

Novo Nordisk AS Investment Alerts

Novo Nordisk AS Upcoming and Recent Events

Novo Largest EPS Surprises

View All Earnings Estimates

Novo Nordisk Environmental, Social, and Governance (ESG) Scores

Novo Nordisk Thematic Classifications

Novo Stock Institutional Investors

Note, although Novo Nordisk's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Novo Market Capitalization

The company currently falls under 'Mega-Cap' category with a total capitalization of 353.42 B.

Novo Profitablity

The company has Net Profit Margin of 0.35 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.5 %, which entails that for every 100 dollars of revenue, it generated $0.5 of operating income.

Management Efficiency

Novo Nordisk AS has Return on Asset of 0.2241 % which means that on every $100 spent on assets, it made $0.2241 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.8078 %, implying that it generated $0.8078 on every 100 dollars invested. Novo Nordisk's management efficiency ratios could be used to measure how well Novo Nordisk manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of March 2025, Return On Equity is likely to grow to 0.74, while Return On Tangible Assets are likely to drop 0.15. At this time, Novo Nordisk's Other Assets are very stable compared to the past year. As of the 22nd of March 2025, Net Tangible Assets is likely to grow to about 37 B, while Return On Tangible Assets are likely to drop 0.15.

Technical Drivers

As of the 22nd of March, Novo Nordisk secures the Mean Deviation of 2.31, risk adjusted performance of (0.10), and Standard Deviation of 3.53. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Novo Nordisk AS, as well as the relationship between them.

Novo Nordisk AS Price Movement Analysis

Novo Nordisk Outstanding Bonds

Novo Nordisk Predictive Daily Indicators

Novo Nordisk Corporate Filings

Novo Nordisk Forecast Models

Novo Nordisk's time-series forecasting models are one of many Novo Nordisk's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Novo Nordisk's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Novo Nordisk prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Novo shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Novo Nordisk. By using and applying Novo Stock analysis, traders can create a robust methodology for identifying Novo entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Novo analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Novo analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Novo Nordisk AS stock analysis indicators help investors evaluate how Novo Nordisk stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Novo Nordisk shares will generate the highest return on investment. By understating and applying Novo Nordisk stock analysis, traders can identify Novo Nordisk position entry and exit signals to maximize returns.

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novo Nordisk. If investors know Novo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novo Nordisk listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Novo Nordisk AS is measured differently than its book value, which is the value of Novo that is recorded on the company's balance sheet. Investors also form their own opinion of Novo Nordisk's value that differs from its market value or its book value, called intrinsic value, which is Novo Nordisk's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novo Nordisk's market value can be influenced by many factors that don't directly affect Novo Nordisk's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.